Stock Earnings
Sharp decrease in NKTR’s short interest leads to decline in days-to-cover ratio
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Menu
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May 19
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May 19
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nektar Therapeutics